Regeneron Pharmaceuticals Inc. closed 54.89% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

Three YPIE RegeneronScience Research Scholars, Loremy, Adrianna, and Maya were accepted to State Senate Majority ...

The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...

WNBF News Radio 1290 AM & 92.1 FM in Binghamton will remain the radio home of Binghamton Rumble Ponies baseball.

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Regeneron Pharmaceuticals Inc. and the New York Division of Taxation both failed to convince a state administrative law judge ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profitable stocks to buy according to analysts. We recently ...